Paul Anantharajah Tambyah

Tambyah Paul Anantharajah

Appointment(s)
  • Professor, Department of Medicine
  • Senior Consultant, Division of Infectious Disease, University Medicine Cluster, National University Health System
Joint Appointment(s)
  • Visiting Consultant, Singapore Armed Forces
Academic Qualifications
  • MBBS, National University of Singapore, Singapore
  • MD, National University of Singapore, Singapore
  • Diplomate, American Board of Internal Medicine and Infectious Diseases, USA
Research Interest(s)
  • Influenza
  • Dengue
  • Catheter-associated UTI
Recent Publications
  • 1. Tan AL, Yoong J, Kasim J, Ciccone G, Sng JG, Tambyah PA. 2015 Dec. Is Measles IgG Testing for Healthcare Providers Cost-Effective? Results From Seroprevalence Studies of Healthcare Providers in a Tertiary Public Hospital With a Large Foreign-Born Workforce. Infect Control Hosp Epidemiol. 36(12):1468-71. doi: 10.1017/ice.2015.206. 26329809.
  • 2. Tong PS, Kale AS, Ng K, Loke AP, Choolani MA, Lim CL, Chan YH, Chong YS, Tambyah PA, Yong EL. 2015 Nov. Respiratory consequences of N95-type Mask usage in pregnant healthcare workers-a controlled clinical study. Antimicrob Resist Infect Control. 4:48. doi: 10.1186/s13756-015-0086-z. 26579222.
  • 3. Gorny AW, Mittal C, Saw S, Venkatachalam I, Fisher DA, Tambyah PA. 2015 Nov. Varicella seroprevalence in healthcare workers in a tertiary hospital: an audit of cross-sectional data. BMC Res Notes. 8:664. doi: 10.1186/s13104-015-1656-0. 26555677.
  • 4. Tartari E, Allegranzi B, Ang B, Calleja N, Collignon P, Hopman J, Lang L, Lee LC, Ling ML, Mehtar S, Tambyah PA, Widmer A, Voss A. 2015 Jun. Preparedness of institutions around the world for managing patients with Ebola virus disease: an infection control readiness checklist. Antimicrob Resist Infect Control. 4:22. doi: 10.1186/s13756-015-0061-8. 26056563.
  • 5. Harris PN, Yin M, Jureen R, Chew J, Ali J, Paynter S, Paterson DL, Tambyah PA. 2015 May. Comparable outcomes for ß-lactam/ß-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrob Resist Infect Control. 4:14. doi: 10.1186/s13756-015-0055-6. 25932324.